[1] Z. D. Kobalava et al., “Arterial hypertension in adults. Clinical guidelines 2020,” Russ. J. Cardiol., vol. 25, no. 3, p. 149, 2020, doi: 10.15829/1560-4071-2020-33786.
[2] W. F. Young, A. W. Stanson, G. B. Thompson, C. S. Grant, D. R. Farley, and J. A. Van Heerden, “Role for adrenal venous sampling in primary aldosteronism,” Surgery, vol. 136, no. 6, pp. 1227-1235, 2004, doi: 10.1016/j.surg.2004.06.051.
[3] A. Hannemann and H. Wallaschofski, “Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies - A review of the current literature,” Horm. Metab. Res., vol. 44, no. 3, pp. 157-162, 2012, doi: 10.1055/s-0031-1295438.
[4] B. M. Shifman, N. M. Platonova, N. V. Molashenko, E. A. Troshina, N. Y. Romanova, and G. S. Kolesnikova, “Aldosterone-and cortisol-co-secreting adrenal tumors: An uneasy sum of well-known parts (review),” Probl. Endokrinol. (Mosk)., vol. 65, no. 2, pp. 113-123, 2019, doi: 10.14341/probl10036.
[5] C. E. Fardella, M. Pinto, L. Mosso, C. Gomez-Sanches, J. Jalil, and J. Montero, “Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric cyp11b1/cyp11b2 gene,” J. Clin. Endocrinol. Metab., vol. 86, no. 10, pp. 4805-4807, 2001, doi: 10.1210/jcem.86.10.7920.
[6] R. G. Dluhy, B. Anderson, B. Harlin, J. Ingelfinger, and R. Lifton, “Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood,” J. Pediatr., vol. 138, no. 5, pp. 715-720, 2001, doi: 10.1067/mpd.2001.112648.
[7] C. Ter Chao et al., “Diagnosis and management of primary aldosteronism: An updated review,” Ann. Med., vol. 45, no. 4, pp. 375-383, 2013, doi: 10.3109/07853890.2013.785234.
[8] P. Milliez, X. Girerd, P. F. Plouin, J. Blacher, M. E. Safar, and J. J. Mourad, “Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism,” J. Am. Coll. Cardiol., vol. 45, no. 8, pp. 1243-1248, 2005, doi: 10.1016/j.jacc.2005.01.015.
[9] J. W. Funder et al., “The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline,” J. Clin. Endocrinol. Metab., vol. 101, no. 5, pp. 1889-1916, 2016, doi: 10.1210/jc.2015-4061.
[10] J. W. Funder et al., “Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline,” J. Clin. Endocrinol. Metab., vol. 93, no. 9, pp. 3266-3281, 2008, doi: 10.1210/jc.2008-0104.
[11] P. Mulatero et al., “Prevalence and characteristics of familial hyperaldosteronism: The PATOGEN study (Primary aldosteronism in TOrino-GENetic forms),” Hypertension, vol. 58, no. 5, pp. 797-803, 2011, doi: 10.1161/HYPERTENSIONAHA.111.175083.
[12] J. M. Fuhrman Kirk; Davis, Allinson, “A chimaeric 11в— hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension,” Nature, vol. 359, pp. 710-713, 1992, [Online]. Available: file:///C:/Users/ASUS/Desktop/Rujukan PhD/p21/xiong1993.pdf.
[13] G. T. McMahon and R. G. Dluhy, “Glucocorticoid-Remediable Aldosteronism,” Cardiol. Rev., vol. 12, no. 1, pp. 44-48, 2004, doi: 10.1097/01.crd.0000096417.42861.ce.
[14] A. So et al., “Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity,” J. Hypertens., vol. 23, no. 8, pp. 1477-1484, 2005, doi: 10.1097/01.hjh.0000174299.66369.26.
[15] M. Stowasser et al., “High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients,” J. Hypertens., vol. 21, no. 11, pp. 2149-2157, 2003, doi: 10.1097/00004872200311000-00025.
[16] A. Tong et al., “A novel phenotype of familial hyperaldosteronism type III: Concurrence of aldosteronism and cushing’s syndrome,” J. Clin. Endocrinol. Metab., vol. 101, no. 11, pp. 4290-4297, 2016, doi: 10.1210/jc.2016-1504.
[17] M. Choi et al., “K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension,” Science (80-. )., vol. 331, no. 6018, pp. 768-772, 2011, doi: 10.1126/science.1198785.
[18] U. I. Scholl et al., “Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5,” Proc. Natl. Acad. Sci. U. S. A., vol. 109, no. 7, pp. 2533-2538, 2012, doi: 10.1073/pnas.1121407109.
[19] W. F. Young, “Diagnosis and treatment of primary aldosteronism: practical clinical perspectives,” J. Intern. Med., vol. 285, no. 2, pp. 126-148, 2019, doi: 10.1111/joim.12831.
[20] S. Davies, “Annals of,” vol. 66, no. 6, pp. 2013-2014, 2013, doi: 10.1258/acb.2012.201227.
[21] G. Berglund, O. Andersson, and L. Wilhelmsen, “Prevalence of primary and secondary hypertension: Studies in a random population sample,” Br. Med. J., vol. 2, no. 6035, pp. 554-556, 1976, doi: 10.1136/bmj.2.6035.554.
[22] C. E. Grim, M. H. Weinberger, J. T. Higgins, and N. J. Kramer, “Diagnosis of Secondary Forms of Hypertension: A Comprehensive Protocol,” JAMA J. Am. Med. Assoc., vol. 237, no. 13, pp. 1331-1335, 1977, doi: 10.1001/jama.1977.03270400035014.
[23] R. D. Gordon, M. Stowasser, T. J. Tunny, S. A. Klemm, and J. C. Rutherford, “High Incidence of Primary Aldosteronism in 199 Patients Referred With Hypertension,” Clin. Exp. Pharmacol. Physiol., vol. 21, no. 4, pp. 315-318, 1994, doi: 10.1111/j.1440-1681.1994.tb02519.x.